Eurofins Scientific SEERFSF +0.21%79 EV-to-EBIT is 18.85 as of Jul. 12, 2026, which is 25% below its 10-year median of 25.00. GuruFocus rates ERFSF with a GF Score™ of 79/100 and a GF Value™ of $78.13 (Fairly Valued). The stock has 7 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks better than 58.65% on this metric.
Eurofins Scientific SE (OTCPK:ERFSF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Eurofins Scientific SE's Enterprise Value for the quarter that ended in Dec. 2025 was $17,253 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eurofins Scientific SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $943 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's EV-to-EBIT falls into.
Eurofins Scientific SE's current Enterprise Value is $17,769 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eurofins Scientific SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $943 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a EV-to-EBIT of 18.85 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eurofins Scientific SE and its competitors. This is 25% below median its historical median of 25.00. Over the past decade, Eurofins Scientific SE's EV-to-EBIT has ranged from 12.53 to 46.05. According to the industry distribution chart, Eurofins Scientific SE ranks #43 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 41.3%.
Is Eurofins Scientific SE's EV-to-EBIT too high?
Eurofins Scientific SE's current EV-to-EBIT of 18.85 is 25% below median its 10-year median of 25.00. Over the past 10 years, this metric has ranged from a low of 12.53 to a high of 46.05. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.67. Eurofins Scientific SE's value of 18.85 is 16.9% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #43 out of 104 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #43 out of 104 companies for EV-to-EBIT. This puts Eurofins Scientific SE in the upper half of its industry. The industry median EV-to-EBIT is 22.67. Eurofins Scientific SE's value of 18.85 is 16.9% below this benchmark. Historically, Eurofins Scientific SE's own EV-to-EBIT has ranged from 12.53 to 46.05 over the past decade. While the company's 10-year median is 25.00 vs. the industry median of 22.67, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.67, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current EV-to-EBIT of 18.85 is 16.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current EV-to-EBIT is 18.85, which is 25% below median its own 10-year median of 25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $78.13, compared to a current price of $80.40 — trading 2.9% above its estimated fair value. The current EV-to-EBIT is 18.85, which is 25% below median its 10-year median of 25.00 and 16.9% below the Medical Diagnostics & Research industry median of 22.67. Eurofins Scientific SE's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current EV-to-EBIT is 18.85 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $80.40 is trading 2.9% above its estimated GF Value™ of $78.13.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
EV-to-EBIT: 18.85 (25% below median its 10-year median of 25.00)
GF Value™: $78.13 vs. price of $80.40 (2.9% above fair value)
Industry Position: 16.9% below the Medical Diagnostics & Research median (#43 of 104)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
79GF Score
Get the complete analysis for ERFSF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
